Imiquimod vs vehicle
Any adverse effect · molluscum contagiosum
Imiquimod showed no clear difference in any adverse effect compared with vehicle (high certainty).
1 finding from 1 review
- RR 0.97 [0.88, 1.07]3 studies · 827 participantsHigh
Findings
What do systematic reviews say?
1,835 questions · 1,886 findings · 74 reviews · Skin
No studies found 542 · 28.7%GRADE not reported 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%
Imiquimod vs vehicle
Adverse effects ‐ application site reaction · molluscum contagiosum
Imiquimod probably leads to higher application site reactions compared with vehicle (moderate certainty).
1 finding from 1 review
- RR 1.41 [1.13, 1.77]3 studies · 827 participantsModerate
Imiquimod vs vehicle
Severe application site reactions · molluscum contagiosum
Imiquimod probably leads to higher severe application site reactions compared with vehicle (moderate certainty).
1 finding from 1 review
- RR 4.33 [1.16, 16.19]3 studies · 827 participantsModerate
Itraconazole (200 mg for 6 to 8 weeks) vs placebo
Percentage of lesions cured after the end of treatment · patients with Old World cutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Paromomycin ointment vs vehicle
Microbiological or histopathological cure of skin lesions · patients with Old World cutaneous leishmaniasis
It is very uncertain whether paromomycin ointment changes microbiological or histopathological cure of skin lesions compared with vehicle (very low certainty).
1 finding from 1 review
- RR 1.03 [0.88, 1.2]2 studies · 383 participantsVery low
Itraconazole (200 mg for 6 to 8 weeks) vs placebo
Proportion of participants with complete cure · patients with Old World cutaneous leishmaniasis
It is very uncertain whether itraconazole (200 mg for 6 to 8 weeks) changes percentage of participants with complete cure compared with placebo (very low certainty).
1 finding from 1 review
- RR 3.7 [0.35, 38.99]3 studies · 244 participantsVery low
Itraconazole (200 mg for 6 to 8 weeks) vs placebo
Adverse effects Mild abdominal pain and nausea Adverse effects Mild abnormal liver function · patients with Old World cutaneous leishmaniasis
It is very uncertain whether itraconazole (200 mg for 6 to 8 weeks) changes adverse effects Mild abdominal pain and nausea Adverse effects Mild… compared with placebo (very low certainty).
1 finding from 1 review
- RR 2.36 [0.74, 7.47]3 studies · 204 participantsVery low
Itraconazole (200 mg for 6 to 8 weeks) vs placebo
Time to complete healing · patients with Old World cutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Itraconazole (200 mg for 6 to 8 weeks) vs placebo
Microbiological or histopathological cure of skin lesions · patients with Old World cutaneous leishmaniasis
It is very uncertain whether itraconazole (200 mg for 6 to 8 weeks) changes microbiological or histopathological cure of skin lesions compared with placebo (very low certainty).
1 finding from 1 review
- RR 17 [0.47, 612.21]1 study · 20 participantsVery low
Paromomycin ointment vs vehicle
Percentage of lesions cured after the end of treatment · patients with Old World cutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Paromomycin ointment vs vehicle
Proportion of participants with complete cure · patients with Old World cutaneous leishmaniasis
It is very uncertain whether paromomycin ointment changes percentage of participants with complete cure compared with vehicle (very low certainty).
1 finding from 1 review
- RR 1 [0.86, 1.17]2 studies · 383 participantsVery low
Paromomycin ointment vs vehicle
Adverse effects Skin/local reactions · patients with Old World cutaneous leishmaniasis
It is very uncertain whether paromomycin ointment changes adverse effects Skin/local reactions compared with vehicle (very low certainty).
1 finding from 1 review
- RR 1.42 [0.67, 3.01]4 studies · 713 participantsVery low
Paromomycin ointment vs vehicle
Time to complete healing · patients with Old World cutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Antibiotic prophylaxis vs no treatment/placebo
Recurrence of cellulitis · People with recurrent erysipelas or cellulitis
Antibiotic prophylaxis probably leads to lower recurrence of cellulitis compared with no treatment/placebo (moderate certainty).
1 finding from 1 review
- Interventions for the prevention of recurrent erysipelas and cellulitis 2017 · Cochrane Headline outcomes onlyRR 0.31 [0.13, 0.72]5 studies · 513 participantsModerate
Antibiotic prophylaxis vs no treatment/placebo
Incidence rate of cellulitis · People with recurrent erysipelas or cellulitis
Antibiotic prophylaxis probably leads to lower incidence rate of cellulitis compared with no treatment/placebo (moderate certainty).
1 finding from 1 review
- Interventions for the prevention of recurrent erysipelas and cellulitis 2017 · Cochrane Headline outcomes onlyRR 0.44 [0.22, 0.89]4 studies · 473 participantsModerate
Antibiotic prophylaxis vs no treatment/placebo
Time to next episode of cellulitis · People with recurrent erysipelas or cellulitis
Antibiotic prophylaxis probably leads to lower time to next episode of cellulitis compared with no treatment/placebo (moderate certainty).
1 finding from 1 review
- Interventions for the prevention of recurrent erysipelas and cellulitis 2017 · Cochrane Headline outcomes onlyHR 0.51 [0.34, 0.78]3 studies · 437 participantsModerate
Antibiotic prophylaxis vs no treatment/placebo
Hospital admissions · People with recurrent erysipelas or cellulitis
Antibiotic prophylaxis showed no clear difference in hospitalisation compared with no treatment/placebo (low certainty).
1 finding from 1 review
- Interventions for the prevention of recurrent erysipelas and cellulitis 2017 · Cochrane Headline outcomes onlyRR 0.77 [0.37, 1.57]3 studies · 429 participantsLow
Antibiotic prophylaxis vs no treatment/placebo
Adverse reactions to treatment Proportion of participants with adverse reactions to treatment · People with recurrent erysipelas or cellulitis
Antibiotic prophylaxis showed no clear difference in any adverse reactions compared with no treatment/placebo (low certainty).
1 finding from 1 review
- Interventions for the prevention of recurrent erysipelas and cellulitis 2017 · Cochrane Headline outcomes onlyRR 0.87 [0.58, 1.3]4 studies · 469 participantsLow
Antibiotic prophylaxis vs no treatment/placebo
Quality of life · People with recurrent erysipelas or cellulitis
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for the prevention of recurrent erysipelas and cellulitis 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Azoles vs terbinafine
Clinical cure · participants with confirmed toenail onychomycosis
Azole probably leads to lower clinical cure compared with terbinafine (moderate certainty).
1 finding from 1 review
- RR 0.82 [0.72, 0.95]15 studies · 2168 participantsModerate